Shares of Second Sight Medical Products Inc. (NASDAQ:EYES) fell 3.1% during mid-day trading on Tuesday . The stock traded as low as $3.96 and last traded at $4.02, with a volume of 166,893 shares traded. The stock had previously closed at $4.15.

Several research firms recently issued reports on EYES. Rodman & Renshaw reiterated a “buy” rating and set a $16.00 price target on shares of Second Sight Medical Products in a research report on Tuesday, July 26th. Zacks Investment Research upgraded shares of Second Sight Medical Products from a “sell” rating to a “hold” rating in a research report on Friday, June 24th.

The stock’s market cap is $150.91 million. The stock has a 50 day moving average of $3.90 and a 200-day moving average of $4.46.

Second Sight Medical Products (NASDAQ:EYES) last issued its quarterly earnings data on Thursday, July 28th. The medical device company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.02. The company had revenue of $1.04 million for the quarter, compared to the consensus estimate of $2.66 million. During the same period in the prior year, the company posted ($0.12) earnings per share. The company’s quarterly revenue was down 63.0% compared to the same quarter last year. Equities research analysts forecast that Second Sight Medical Products Inc. will post ($0.62) earnings per share for the current fiscal year.

In other Second Sight Medical Products news, Chairman Robert J. Greenberg sold 8,571 shares of the business’s stock in a transaction that occurred on Thursday, June 2nd. The shares were sold at an average price of $4.10, for a total value of $35,141.10. Following the completion of the transaction, the chairman now owns 172,911 shares of the company’s stock, valued at approximately $708,935.10. The transaction was disclosed in a filing with the SEC, which is available through this link.

Second Sight Medical Products, Inc is a medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.